Adv Pediatr Surg.
2022 Jun;28(1):31-36. 10.13029/aps.2022.28.1.31.
Sirolimus Treatment of Refractory Infantile Hemangiomatosis With Brain Involvement
- Affiliations
-
- 1Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 2Department of Pediatric Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- KMID: 2538287
- DOI: http://doi.org/10.13029/aps.2022.28.1.31
Abstract
- Infantile hemangiomas are the most common vascular tumors of infants and are characterized by abnormal proliferation of endothelial cells and aberrant blood vessel architecture. The drug Sirolimus has been explored as a new therapeutic option in the management of vascular anomalies that do not respond to conventional treatments. This report presents a case of refractory multiple infantile hemangiomatosis with brain involvement that was successfully treated with sirolimus.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Eruptive Neonatal Hemangiomatosis
- Diffuse Neonatal Hemangiomatosis
- Benign Neonatal Hemagiomatosis with Unusually Persistent Lesions and Conjunctival Hemangioma
- Diffuse Neonatal Hemangiomatosis Successfully Treated with High Dose Corticosteroid
- Diffuse Hemangiomatosis in the Intra-Abdominal Cavity Mimicking Peritoneal Metastasis: A Case Report
